Varela Nelson, Lanas Fernando, Salazar Luis A, Zambrano Tomás
Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
Department of Internal Medicine, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile.
Front Genet. 2020 Jan 10;10:1247. doi: 10.3389/fgene.2019.01247. eCollection 2019.
In-stent restenosis corresponds to the diameter reduction of coronary vessels following percutaneous coronary intervention (PCI), an invasive procedure in which a stent is deployed into the coronary arteries, producing profuse neointimal hyperplasia. The reasons for this process to occur still lack a clear answer, which is partly why it remains as a clinically significant problem. As a consequence, there is a vigorous need to identify useful non-invasive biomarkers to differentiate and follow-up subjects at risk of developing restenosis, and due to their extraordinary stability in several bodily fluids, microRNA research has received extensive attention to accomplish this task. This review depicts the current understanding, diagnostic potential and clinical challenges of microRNA molecules as possible blood-based restenosis biomarkers.
支架内再狭窄是指经皮冠状动脉介入治疗（PCI）后冠状动脉血管直径缩小，PCI是一种侵入性手术，将支架植入冠状动脉，会产生大量新生内膜增生。这一过程发生的原因仍缺乏明确答案，这也是它仍是一个具有临床意义问题的部分原因。因此，迫切需要识别有用的非侵入性生物标志物，以区分和随访有发生再狭窄风险的受试者，由于微小RNA在几种体液中具有非凡的稳定性，微小RNA研究已受到广泛关注以完成这项任务。本综述描述了微小RNA分子作为可能的基于血液的再狭窄生物标志物的当前认识、诊断潜力和临床挑战。
